Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 6/23/02  and contains information from public web pages.

Dr. Nicola Pimpinelli

Wrong Dr. Nicola Pimpinelli?
 
Background

Employment History

  • Associate Professor of Dermatology, Department of Dermatological Sciences
    University of Florence Medical School
  • Associate Professor of Dermatology, Department of Dermatological Sciences
    University of Florence Medical School , Italy
  • Associate Professor, Department of Dermatological Sciences
    University of Florence
  • Florence University Medical Center

Education

  • MD , dermatology , oncology
Web References
DermatologyTimes - No Benefit to Low-Grade Lymphoma Subgroups
www.dermatologytimes.com, 23 June 2002 [cached]
MUNICH - While primary cutaneous B-cell lymphomas must be clearly separated from non-Hodgkin's B-cell lymphomas with secondary cutaneous involvement and from cutaneous B-cell pseudolymphomas, "from the truly clinical and prognostic point of view, low-grade lymphomas are one disease," according to Nicola Pimpinelli, M.D., at the annual meeting of the European Academy of Dermatology and Venereology.
"In our experience," said Dr. Pimpinelli, associate professor of dermatology, department of dermatological sciences, University of Florence Medical School, Italy, "the identification of distinct subgroups is disputable from a strictly histologic, immunophenotypic, and genotypic point of view, and has no correlation with either the clinical course or the prognosis of the disease."He added that the large majority of CBCL show a uniform immunophenotype (CD5-, CD10-) and genotype (lack of bcl-1/bcl-2 and c-myc gene rearrangement) of neoplastic cells.
According to the EORTC classification of primary cutaneous lymphomas, CBCL with indolent behavior are divided into two subgroups, Dr. Pimpinelli explained.These subgroups are the follicular center cell lymphoma and the immunocytoma/marginal zone lymphoma.They are named due to putative histologic similarities with their purported nodal counterparts.
"Generally speaking, more than 90 percent of primary cutaneous B-cell lymphoma have a very good prognosis, independent of their histologic categorization," Dr. Pimpinelli said.Whatever the subgroup, he added, the large majority of CBCL are characterized by a homogeneous clinical presentation and behavior, they have a good response to local radiotherapy, a low tendency to extracutaneous spread, and they have an excellent prognosis."
In a series of patients, local orthovolt radiotherapy produced a complete remission in 98.2 percent of 115 patients treated, Dr. Pimpinelli reported.
"Very often, in the same patient at different time points or even contemporaneously, you can find lesions in which you can make two different diagnoses, follicular center cells in one lesion and marginal zone lymphoma in another," Dr. Pimpinelli said.
Histological (left), and immunohistochemical views.
"No matter if you classify them as follicular center cell lymphoma or marginal zone lymphoma, which are two different subtypes of histologic diagnoses, the clinical appearance, and more important, the clinical outcome, of the disease is exactly the same," he said.These lesions can be treated with surgery if they are isolated, or with radiotherapy, if they are grouped.
...
Dr. Pimpinelli and his colleague, Marco Santucci, M.D., pointed out that it is not so important to have special terms like that - i.e., Skin-Associated Lymphoid Tissue (SALT)-related B-cell lymphoma - on the basis of the close similarities between CBCL and so-called Mucosa-Associated Lymphoid Tissue (MALT)-related B-cell lymphoma.
...
"A further matter of debate is whether the rare, so-called large B-cell lymphoma of the leg - the third subgroup of primary CBCL identified in the EORTC classification - should indeed be regarded as a distinct clinicopathologic entity," Dr. Pimpinelli said.
These patients seem to have an intermediate prognosis, Dr. Pimpinelli said.It is clear that these patients have lesions mostly localized on the legs, with de novo large cell (centroblast-like or immunoblast-like) histology, and they are very often older than 70.This makes it difficult to treat these patients long term."In fact, sometimes radiotherapy gives some very good results, but you can have very quick relapses and you are concerned to treat them again with radiotherapy because of problems of cumulative dosage.On the other hand, effective chemotherapy cannot be reasonably proposed due to a the old age of these patients."Care for these patients, who are sometimes 75 to 80 years old, can be therefore a problem from a management point of view."The prognosis of these patient is heavily conditioned from the age of the patients," Dr. Pimpinelli said.DT
For more information
Pimpinelli N, Santucci M. The skin-associated lymphoid tissue-related B-cell lymphomas.Semin Cutan Med Surg.2000 Jun;19(2):124-129.
DermatologyTimes - No Benefit to Low-Grade Lymphoma Subgroups
www.dermatologytimes.com, 1 Dec 2001 [cached]
MUNICH - While primary cutaneous B-cell lymphomas must be clearly separated from non-Hodgkin's B-cell lymphomas with secondary cutaneous involvement and from cutaneous B-cell pseudolymphomas, "from the truly clinical and prognostic point of view, low-grade lymphomas are one disease," according to Nicola Pimpinelli, M.D., at the annual meeting of the European Academy of Dermatology and Venereology.
"In our experience," said Dr. Pimpinelli, associate professor of dermatology, department of dermatological sciences, University of Florence Medical School, Italy, "the identification of distinct subgroups is disputable from a strictly histologic, immunophenotypic, and genotypic point of view, and has no correlation with either the clinical course or the prognosis of the disease."He added that the large majority of CBCL show a uniform immunophenotype (CD5-, CD10-) and genotype (lack of bcl-1/bcl-2 and c-myc gene rearrangement) of neoplastic cells.
According to the EORTC classification of primary cutaneous lymphomas, CBCL with indolent behavior are divided into two subgroups, Dr. Pimpinelli explained.These subgroups are the follicular center cell lymphoma and the immunocytoma/marginal zone lymphoma.They are named due to putative histologic similarities with their purported nodal counterparts.
"Generally speaking, more than 90 percent of primary cutaneous B-cell lymphoma have a very good prognosis, independent of their histologic categorization," Dr. Pimpinelli said.Whatever the subgroup, he added, the large majority of CBCL are characterized by a homogeneous clinical presentation and behavior, they have a good response to local radiotherapy, a low tendency to extracutaneous spread, and they have an excellent prognosis."
In a series of patients, local orthovolt radiotherapy produced a complete remission in 98.2 percent of 115 patients treated, Dr. Pimpinelli reported.
"Very often, in the same patient at different time points or even contemporaneously, you can find lesions in which you can make two different diagnoses, follicular center cells in one lesion and marginal zone lymphoma in another," Dr. Pimpinelli said.
Histological (left), and immunohistochemical views.
"No matter if you classify them as follicular center cell lymphoma or marginal zone lymphoma, which are two different subtypes of histologic diagnoses, the clinical appearance, and more important, the clinical outcome, of the disease is exactly the same," he said.These lesions can be treated with surgery if they are isolated, or with radiotherapy, if they are grouped.
...
"A further matter of debate is whether the rare, so-called large B-cell lymphoma of the leg - the third subgroup of primary CBCL identified in the EORTC classification - should indeed be regarded as a distinct clinicopathologic entity," Dr. Pimpinelli said.
These patients seem to have an intermediate prognosis, Dr. Pimpinelli said.It is clear that these patients have lesions mostly localized on the legs, with de novo large cell (centroblast-like or immunoblast-like) histology, and they are very often older than 70.This makes it difficult to treat these patients long term."In fact, sometimes radiotherapy gives some very good results, but you can have very quick relapses and you are concerned to treat them again with radiotherapy because of problems of cumulative dosage.On the other hand, effective chemotherapy cannot be reasonably proposed due to a the old age of these patients."Care for these patients, who are sometimes 75 to 80 years old, can be therefore a problem from a management point of view."The prognosis of these patient is heavily conditioned from the age of the patients," Dr. Pimpinelli said.DT
For more information
Pimpinelli N, Santucci M. The skin-associated lymphoid tissue-related B-cell lymphomas.Semin Cutan Med Surg.2000 Jun;19(2):124-129.
Cutaneous Lymphoma Foundation
www.clfoundation.org, 21 Aug 2006 [cached]
c/o Nicola Pimpinelli, MD Associate Professor Dept. of Dermatological Sciences University of Florence
...
Nicola Pimpinelli, MD (dermatology, oncology)
Nicola Pimpinelli, ...
www.cutaneouslymphoma.org, 23 Mar 2014 [cached]
Nicola Pimpinelli, MD
Associate Professor of Dermatology Dept. of Dermatological Sciences Director Skin Cancer Unit Florence University Medical Center
Other People with the name "Pimpinelli":
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304